SAN DIEGO, Sept. 16, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA) today announced the expansion of its Executive Team with the appointment of Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer.
Dr. Lee has more than 20 years of professional experience, with a particular focus on oncology, including clinical development and regulatory strategies and execution of phase I-IV clinical trials that lead to 4 NDAs for several major products in oncology such as taxotere and Zytiga. Her experience also includes franchise development especially in the areas of competitive landscape analysis, and technology assessment.
"Dr. Lee's extensive experience in oncology clinical research and development comes at exactly the right time to HUYA as we advance our lead anticancer drug, the novel oral HDAC inhibitor with immunomodulatory properties, HBI-8000, through clinical trials," said Mireille Gillings Ph.D., CEO of HUYA. "We welcome her to the HUYA Executive team, where she joins Bob Goodenow, Ph.D., Chief Business Officer; Alain Rolland, Pharm.D., Ph.D., Executive Vice President and Chief Scientific Officer; Mr. John Sharp, CPA, Chief Financial Officer; and Mr. Clem Gingras, Chief Technology Officer & Chief Operating Officer, Asia."
Most recently, Dr. Lee was Chief Medical Officer at Beyondspring Pharmaceuticals; she was also the first CMO at Kite Pharma. She held leadership positions in, Cougar Biotechnology (acquired by Johnson & Johnson), Hoffmann-La Roche, Rhone Poulenc-Rorer (now Sanofi-Aventis).
Educated in Florida, New York and Taiwan, Dr. Lee holds an M.D. from the University of Miami School of Medicine (Miami, Florida), an Ph.D in Molecular Biology from Columbia University (New York City), and a B.S. in Agricultural Chemistry from the National Taiwan University in Taipei. Postgraduate training included periods at Fox Chase Cancer Center, Georgetown University Hospital and the University of Chicago.
About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards. www.huyabio.com
HUYA Corporate Communications
+1 858 353 1217